Axim Biotechnologies annual return on equity
2012
Axim Biotechnologies Return on Equity (ROE) Growth & History (AXIM)
Axim Biotechnologies's return on equity was −541.18% for fiscal 2012.
View full Axim Biotechnologies company overviewAxim Biotechnologies annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2012 | 2012-12-31 | −541.18% | — |
Axim Biotechnologies quarterly return on equity
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q3.15
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2021 | 2021-12-31 | −697.06% | −572.67 pp |
| Q3 2021 | 2021-09-30 | −115.80% | +0.16 pp |
| Q2 2021 | 2021-06-30 | −287.08% | −262.17 pp |
| Q1 2021 | 2021-03-31 | −54.13% | — |
| Q4 2020 | 2020-12-31 | −124.39% | — |
| Q3 2020 | 2020-09-30 | −115.96% | — |
| Q2 2020 | 2020-06-30 | −24.91% | — |
| Q3 2015 | 2015-09-30 | −4,193.58% | — |
| Q4 2012 | 2012-12-31 | −113.23% | −125.92 pp |
| Q3 2012 | 2012-09-30 | −16.58% | +72.69 pp |
| Q2 2012 | 2012-06-30 | −46.03% | — |
| Q1 2012 | 2012-03-31 | −47.00% | — |
| Q4 2011 | 2011-12-31 | 12.69% | — |
| Q3 2011 | 2011-09-30 | −89.27% | — |
Axim Biotechnologies return on equity trends
The latest reported quarter, Q4 2021, shows −697.06%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Axim Biotechnologies source filings ↗